iBio, Inc.
IBIONasdaq
$1.38
↑ +2.2%Jul 17 close · end-of-day
Price
1Y↑ +88.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$165.0M
Enterprise Value
$90.2M
P/E
—
P/S
550.2
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
-13.4%
Dividend Yield
—
Revenue (TTM)
$300,000.00
Net Income (TTM)
-$27.6M
Free Cash Flow (TTM)
-$22.2M
Gross Margin
—
Operating Margin
-9653.0%
Net Margin
-9202.0%
ROE
-35.6%
ROIC
-841.4%
Debt / Equity
—
Net Cash
$74.8M
Return 1Y
+89.0%
Company profile
iBio, Inc. provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.
- CEO
- Thomas F. Isett
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- New York
- Website
- ibioinc.com
Management & directors
- Banjak MarcChief Legal Officer
- Brenner MartinSee Remarks
- Duran FelipeChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
IBIO Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.06↓ -87.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.4M | $1.9M | $0.00 | $225,000.00 | $400,000.00 |
| Gross profit | $909,000.00 | $2.2M | — | — | — |
| Operating income | -$31.1M | -$29.7M | -$29.3M | -$16.6M | -$18.6M |
| Net income | -$23.2M | -$50.3M | -$65.0M | -$24.9M | -$18.4M |
| Diluted EPS | -$3.00 | -$5.78 | -$106.19 | -$6.50 | -$1.75 |
| Operating cash flow | -$30.1M | -$37.5M | -$30.4M | -$18.6M | -$15.3M |
| Free cash flow | -$35.0M | -$44.8M | -$36.2M | -$18.8M | -$15.3M |
| Gross margin | 38.3% | 115.0% | — | — | — |
| Operating margin | -1312.1% | -1576.3% | — | -7392.9% | -4650.5% |
| Net margin | -978.8% | -2670.0% | — | -11069.8% | -4594.3% |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $175,000.00 | $0.00 | $200,000.00 | $0.00 | $200,000.00 | $100,000.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.4M | -$4.1M | -$4.4M | -$4.9M | -$5.2M | -$6.0M | -$9.4M | -$8.4M |
| Net income | -$7.8M | -$4.0M | -$4.4M | -$4.9M | -$5.2M | -$5.7M | -$9.0M | -$7.7M |
| Diluted EPS | $3.57 | -$0.46 | -$0.48 | -$0.49 | -$0.32 | -$0.11 | -$0.09 | -$0.06 |
| Operating cash flow | -$4.9M | -$3.7M | -$3.9M | -$3.1M | -$4.6M | -$5.7M | -$5.2M | -$6.1M |
| Free cash flow | — | -$3.7M | -$3.9M | -$3.1M | -$4.6M | -$5.7M | -$5.8M | -$6.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1948.0% | — | -2209.5% | — | -2599.0% | -5951.0% | — | — |
| Net margin | -4444.6% | — | -2182.0% | — | -2581.5% | -5720.0% | — | — |
Company news
Jun 2, 2026
May 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-26 | Banjak Marc· Chief Legal Officer | Buy | 12,500 | $1.64 | $20,531.25 | filing |
| 2026-03-26 | Banjak Marc· Chief Legal Officer | Buy | 1,434 | $1.76 | $2,523.84 | filing |
| 2026-03-19 | Duran Felipe· Chief Financial Officer | Buy | 24,835 | $2.02 | $50,131.93 | filing |
| 2026-03-19 | Brenner Martin· See Remarks | Buy | 12,336 | $2.02 | $24,918.72 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.